

NEWS RELEASE

FOR IMMEDIATE RELEASE

December 19, 2016

Methapharm Launches CUROSURF® in Canada

Methapharm is pleased to announce that it has launched CUROSURF® (poractant alfa) in Canada. CUROSURF® is the only porcine-based lung surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Developed by Chiesi Farmaceutici, CUROSURF® is now available in ninety countries worldwide. Chiesi appointed Methapharm as the Canadian distributor for CUROSURF® earlier this year.

About Chiesi Farmaceutici S.p.A

Headquartered in Parma, Italy Chiesi Farmaceutici is an international research-focused Healthcare group, with over 80 years of experience in the pharmaceutical industry. Chiesi researches, develops, and markets innovative drugs in the respiratory therapeutics, specialist medicine, and rare diseases areas. Its R&D centres in Parma (Italy), Paris (France), Cary (USA), Chippenham (UK) and the R&D team of the acquired Danish company Zymenex, integrate the group's efforts to advance Chiesi's pre-clinical, clinical, and registration programs. Chiesi has affiliates in twenty-six countries and exports products to over seventy countries. The group employs over 4,500 people, 560 of whom are solely dedicated to research and development activities.

About Methapharm Inc.

Methapharm is a privately held specialty pharmaceutical company that focuses on the acquisition, licensing, and promotion of healthcare products in North America. Methapharm markets its own proprietary products as well as partners with global companies in order to deliver a line of specialty products. The launch of CUROSURF® is in keeping with Methapharm's mission to make specialty products available to practitioners in the markets we serve.

###

For more information about Methapharm or business development inquiries, please contact:

Chris Calenti

Exec. Vice President

Tel: (+1) 519.751.3602 x7222

For more information on CUROSURF®: Please consult the product monograph available on our website at www.methapharm.com for important information relating to adverse reactions, drug interactions, and dosing information. The product monograph is also available by calling us at 1-800-287-7686 ext 7804.